Opioids and Cancer Mortality
Authors:
- 20 February 2020
- journal article
- review article
- Published by Springer Nature in Current Treatment Options in Oncology
- Vol. 21 (3) , 22
Abstract
Opioids are the gold standard for the treatment of cancer-related pain. Preclinical studies have associated opioids with cancer progression and overall survival. In mice models, opioids have been shown to possess pro-tumor activity secondary to immunosuppression, migration of tumor cells, increased activity of vascular endothelial growth factor receptors, and angiogenesis leading to tumor progression. In contrast, opioids have also been associated with having antitumor activity by activation of apoptosis and phagocytosis. However, high-quality randomized controlled trials in humans that are focused on the association between opioids and survival in cancer patients are lacking, which underscores the importance of being cautious when interpreting the results of the preclinical studies. Cancer-related pain is complex and multifactorial and may worsen as the disease progresses leading to higher opioid utilization. Moreover, cancer pain by itself has been associated with poor survival. The survival in these advanced cancer patients taking opioids may be more likely to be associated with cancer progression and not the opioid use. Adequate treatment of cancer pain has the potential to improve quality of life and performance status, highlighting the importance of continuing to use opioids to manage pain efficiently. More research is clearly needed.Keywords
This publication has 89 references indexed in Scilit:
- Molecular Mechanisms of Opioid Receptor-dependent Signaling and BehaviorAnesthesiology, 2011
- The Novel Role of the Mu Opioid Receptor in Lung Cancer ProgressionAnesthesia & Analgesia, 2011
- Tramadol and Flurbiprofen Depress the Cytotoxicity of Cisplatin via Their Effects on Gap JunctionsClinical Cancer Research, 2009
- Epithelial-Mesenchymal TransitionCancer Research, 2008
- Opioid-induced immunosuppressionCurrent Opinion in Supportive & Palliative Care, 2008
- COX-2 inhibitor celecoxib prevents chronic morphine-induced promotion of angiogenesis, tumour growth, metastasis and mortality, without compromising analgesiaBritish Journal of Cancer, 2007
- Functional Expression of μ-Opioid Receptors in the Human Colon Cancer Cell Line, HT-29, and their Localization in Human ColonDigestive Diseases and Sciences, 2007
- Methylnaltrexone inhibits opiate and VEGF-induced angiogenesis: Role of receptor transactivationMicrovascular Research, 2006
- Implantable Drug Delivery Systems (IDDS) After Failure of Comprehensive Medical Management (CMM) Can Palliate Symptoms in the Most Refractory Cancer Pain PatientsJournal of Palliative Medicine, 2005
- Mu-Opioid Receptor-Mediated Phosphorylation of IκB Kinase in Human Neuroblastoma SH-SY5Y CellsNeurosignals, 2005